网站综合信息 www.mappharma.com
- 标题:
- Allergan - Allergan, Inc. to Acquire M
- 关键字:
- 描述:
- MAP Pharmaceuticals uses proprietary inhalation technologies to enhance the therapeutic benefits and
- 域名信息
- 域名年龄:21年 注册日期:2004年01月23日 到期时间:2023年01月23日
邮箱:compliance 电话:+1.2083895740
注册商:MARKMONITOR INC.
- 服务器空间
- IP:162.116.190.157 同IP网站2个 详情
地址:美国
- 备案信息
- 备案号:
域名流量Alexa排名
域名注册Whois信息
mappharma.com
域名年龄: 21年注册时间: 2004-01-23
到期时间: 2023-01-23
注 册 商: MARKMONITOR INC.
注册邮箱: compliance
联系电话: +1.2083895740
获取时间: 2014年04月12日 01:33:10
Domain Name: MAPPHARMA.COM
Registrar: MARKMONITOR INC.
Whois Server: whois.markmonitor.com
Referral URL: http://www.markmonitor.com
Name Server: NS1.MARKMONITOR.COM
Name Server: NS2.MARKMONITOR.COM
Name Server: NS3.MARKMONITOR.COM
Name Server: NS4.MARKMONITOR.COM
Name Server: NS5.MARKMONITOR.COM
Name Server: NS6.MARKMONITOR.COM
Status: clientDeleteProhibited
Status: clientTransferProhibited
Status: clientUpdateProhibited
Updated Date: 2013-05-28
Creation Date: 2004-01-23
Expiration Date: 2023-01-23
>>> Last update of whois database: Fri, 2014-Apr-11 17:37:06 UTC <<<
Domain Name: mappharma.com
Registry Domain ID: 110443576_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2013-12-19T10:45:01-0800
Creation Date: 2013-05-28T12:41:19-0700
Registrar Registration Expiration Date: 2023-01-23T07:44:56-0800
Registrar: MarkMonitor, Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: compliance
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientUpdateProhibited
Domain Status: clientTransferProhibited
Domain Status: clientDeleteProhibited
Registry Registrant ID:
Registrant Name: Domain Administrator
Registrant Organization: Allergan, Inc.
Registrant Street: 2525 Dupont Drive,
Registrant City: Irvine
Registrant State/Province: CA
Registrant Postal Code: 92612
Registrant Country: US
Registrant Phone: +1.7142466799
Registrant Phone Ext:
Registrant Fax: +1.7142462418
Registrant Fax Ext:
Registrant Email: domainmanager
Registry Admin ID:
Admin Name: Domain Administrator
Admin Organization: Allergan, Inc.
Admin Street: 2525 Dupont Drive,
Admin City: Irvine
Admin State/Province: CA
Admin Postal Code: 92612
Admin Country: US
Admin Phone: +1.7142466799
Admin Phone Ext:
Admin Fax: +1.7142462418
Admin Fax Ext:
Admin Email: domainmanager
Registry Tech ID:
Tech Name: Domain Administrator
Tech Organization: Allergan, Inc.
Tech Street: 2525 Dupont Drive,
Tech City: Irvine
Tech State/Province: CA
Tech Postal Code: 92612
Tech Country: US
Tech Phone: +1.7142466799
Tech Phone Ext:
Tech Fax: +1.7142462418
Tech Fax Ext:
Tech Email: domainmanager
Name Server: ns5.markmonitor.com
Name Server: ns1.markmonitor.com
Name Server: ns4.markmonitor.com
Name Server: ns6.markmonitor.com
Name Server: ns2.markmonitor.com
Name Server: ns3.markmonitor.com
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2014-04-11T10:37:38-0700 <<<
MarkMonitor is the Global Leader in Online Brand Protection.
MarkMonitor Domain Management(TM)
MarkMonitor Brand Protection(TM)
MarkMonitor AntiPiracy(TM)
MarkMonitor AntiFraud(TM)
Professional and Managed Services
Visit MarkMonitor at http://www.markmonitor.com
Contact us at +1.8007459229
In Europe, at +44.02032062220
网站头文件(HTTP Header)
HTTP/1.0 302 Found 目标网址:http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=735125 服务器:BigIP 连接:Keep-Alive 文件大小:0 HTTP/1.1 200 OK 连接:关闭 访问时间:2014年04月12日 09:46:23 类型:text/html; charset=UTF-8 服务器:Microsoft-IIS/6.0 语言环境:ASP.NET 设置Cookie:AGN_SESSION=3085870052%7C%20%7Bts%20%272014%2D04%2D11%2021%3A46%3A23%27%7D%7C%20%7Bts%20%272014%2D04%2D11%2021%3A46%3A23%27%7D%7C8B251013F9F7196CCB85387EC9552435; HttpOnly;domain=agn.client.shareholder.com;expires=Sun, 12-Apr-2015 01:46:23 GMT;path=/ 设置Cookie:AGN_BRIEFCASE=UPDATED%7C41650%2E9072106;domain=agn.client.shareholder.com;expires=Sun, 12-Apr-2015 01:46:23 GMT;path=/ 设置Cookie:AGN_PREVIEW=;expires=Fri, 12-Apr-2013 01:46:23 GMT;path=/ Content-Encoding: gzip 动作:Accept-Encoding Transfer-Encoding: chunked 网站编码:UTF-8 页面编码:iso-8859-1
同IP网站(同服务器)
其他后缀域名
网站首页快照(纯文字版)
抓取时间:2014年04月12日 09:41:55
网址:http://www.mappharma.com/
标题:Allergan - Allergan, Inc. to Acquire MAP Pharmaceuticals, In
关键字:
描述:MAP Pharmaceuticals uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by ...
主体:
网址:http://www.mappharma.com/
标题:Allergan - Allergan, Inc. to Acquire MAP Pharmaceuticals, In
关键字:
描述:MAP Pharmaceuticals uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by ...
主体:
Skip to contentGlobal Locations Contact UsSearch About UsHistory Leadership Global Locations What We TreatEye Care:Dry Eye Glaucoma Other Eye Conditions Neurosciences:Blepharospasm Cervical Dystonia StrabismusObesity Intervention Medical Aesthetics:Breast Aesthetics Facial Aesthetics Medical Dermatology:Acne Psoriasis Severe Primary Axillary Hyperhidrosis Other Skin Conditions Urologics:Overactive BladderProductsEye Care Neurosciences Obesity Intervention Medical Aesthetics: Breast and Facial Medical DermatologyUrologicsR&DPipeline Corporate Research Collaborations Allergan Clinical Trials Excellence in ResearchNewsroom Fast Facts Press Releases Investors Earnings Releases Stock Information Financial Reports Non-GAAP Financial Reconciliation Corporate Governance & Certificates Webcasts & Transcripts Analyst Coverage Shareholder Information Contact Information ResponsibilityAllergan Foundation Patient Resources Physician Resources Professional Affiliations Unrestricted Educational Grants Political Contributions Compliance Environmental Health and Safety Animal Testing CareersCulture Benefits Recognizing Excellence Job Search My Candidate Profile My Waco Profile FAQ -->-->-->-->In this Section:Overview Fast FactsPress Releases2013201220112010 2009 2008 2007 2006 2005 ArchivesRelated Links:Corporate Overview Leadership PipelineAllergan, Inc. to Acquire MAP Pharmaceuticals, Inc.Acquisition Enhances Allergan Leadership Position in Neurology andMigraine SpecialtyIRVINE, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP)today jointly announced that they have entered into a definitive mergeragreement whereby Allergan will acquire 100% of the shares of MAPPharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals isa biopharmaceutical company focused on developing and commercializingnew therapies in Neurology, including LEVADEX®, an orally inhaled drugfor the potential acute treatment of migraine in adults. LEVADEX® iscurrently under review with the U.S. Food and Drug Administration (FDA).The transaction, which has been unanimously approved by the boards ofdirectors of both companies, will be accomplished pursuant to a cashtender offer followed by a second step merger. The per share cash offerprice represents a 60% premium over MAP's closing stock price on theNasdaq Stock Market of $15.58 on January 22, 2013, and represents atotal equity value of approximately $958 million, on a fully-dilutedbasis. The acquisition is expected to close late in the first quarter orin the second quarter of 2013."One of the key drivers of Allergan's continued success is our focus onmedical specialties where we have extensive knowledge of physician andpatient needs, and can provide a broad portfolio of products," saidDavid E.I. Pyott, Chairman of the Board, President and Chief ExecutiveOfficer, Allergan. "Allergan has a record of leadership in theNeurosciences fie
最近查询网站